ADMA Biologics, Inc. Free Cash Flow 2011–2025
ADMA Biologics, Inc. reported $27.82M of free cash flow for fiscal 2025. That was 74.8% lower than fiscal 2024. Compared with fiscal 2020, the change was +124.2%.
| Fiscal year | Free Cash Flow | Change (YoY) |
|---|---|---|
| FY 2025 | $27.82M | -74.8% |
| FY 2024 | $110.45M | +2641.3% |
| FY 2023 | $4.03M | +105.5% |
| FY 2022 | $-73.42M | +41.7% |
| FY 2021 | $-125.88M | -9.7% |
| FY 2020 | $-114.73M | -43.4% |
| FY 2019 | $-80.01M | -23.5% |
| FY 2018 | $-64.77M | -62.1% |
| FY 2017 | $-39.95M | -117.8% |
| FY 2016 | $-18.34M | -18.8% |
| FY 2015 | $-15.44M | +9.3% |
| FY 2014 | $-17.03M | -53.6% |
| FY 2013 | $-11.08M | -57.8% |
| FY 2012 | $-7.02M | -390.6% |
| FY 2011 | $-1.43M | — |
Source: ADMA Biologics, Inc. SEC filings — cash flow statement (10-K). Computed deterministically; refreshed nightly (last updated August 2, 2026). Open ADMA 10-K filings at SEC EDGAR · Methodology · Download CSV.
How to read this history
ADMA Biologics, Inc. reported $27.82M of free cash flow for fiscal 2025. That was 74.8% lower than fiscal 2024. Compared with fiscal 2020, the change was +124.2%. Values remain missing when the cached filing does not disclose a comparable line item; they are never estimated. Stock splits, reorganizations and fiscal-calendar changes can reduce comparability.
Prepared and reviewed by the stockportfolio.pro research desk. Corrections: support@stockportfolio.pro.
See the full picture for ADMA Biologics, Inc.
Complete income statement, balance sheet and cash flow with trend on every row, 48 quarters, ratios, health checks, and Ask — the SEC-grounded research assistant.
Open the interactive view — freeADMA Biologics, Inc. — frequently asked questions
What is ADMA Biologics, Inc.'s free cash flow?
ADMA Biologics, Inc. (ADMA) reported free cash flow of $27.82M for fiscal year 2025, per its SEC filings.
Where does this data come from?
Figures are computed from ADMA Biologics, Inc.'s official SEC filings (cash flow statement (10-K)), refreshed nightly. Not investment advice.